These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18665149)

  • 1. International guidelines on access to biologic therapy: why the differences and which is best?
    Deighton C; Hyrich K
    Nat Clin Pract Rheumatol; 2008 Oct; 4(10):520-1. PubMed ID: 18665149
    [No Abstract]   [Full Text] [Related]  

  • 2. The pitfalls in the development of biologic therapy.
    Maini RN; Feldmann M
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998
    [No Abstract]   [Full Text] [Related]  

  • 3. Towards international guidelines for the management of psoriatic arthritis.
    Gladman DD; Mease PJ
    J Rheumatol; 2006 Jul; 33(7):1228-30. PubMed ID: 16821263
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis.
    Franklin G; Greenspan J; Chen S
    Ann Clin Lab Sci; 2009; 39(2):192-5. PubMed ID: 19429808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why do some biologic agents induce psoriasis or psoriasiform lesions?
    Laurindo IM; Scheinberg M
    Nat Clin Pract Rheumatol; 2008 Apr; 4(4):168-9. PubMed ID: 18253108
    [No Abstract]   [Full Text] [Related]  

  • 8. Rheumatoid arthritis: International disparities in access to anti-TNF therapy.
    Emery P
    Nat Rev Rheumatol; 2011 Apr; 7(4):197-8. PubMed ID: 21455248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 12. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of periodontoid pannus with infliximab in a patient with rheumatoid arthritis.
    Salli A; Sahin N; Paksoy Y; Kucuksarac S; Ugurlu H
    J Clin Rheumatol; 2009 Aug; 15(5):250-1. PubMed ID: 19590438
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 17. Robin goodfellow.
    Rheumatology (Oxford); 2001 Jul; 40(7):838. PubMed ID: 11477300
    [No Abstract]   [Full Text] [Related]  

  • 18. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hotel-based rheumatology, and more.
    Leeb BF
    J Rheumatol; 2009 Feb; 36(2):455-6; author reply 456-7. PubMed ID: 19208582
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening for Mycobacterium tuberculosis prior to anti-TNF therapy--an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence.
    Pradeep JD; Clunie GP; Gaffney K; Innes NJ; Brooksby A; Bradley P; Gulati A
    Rheumatology (Oxford); 2009 Feb; 48(2):195. PubMed ID: 19033354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.